Why a Detectable HIV Test Result Can Mean the Virus Is Already Broken

For someone living with HIV, the number on a blood test can run their whole week. The drugs are supposed to push the virus below the threshold a machine can see, and most of the time they do. So when the lab comes back with a reading above 20 copies per millilitre, the worry sets in. Has the treatment failed? Is the virus loose again, ready to infect a partner?

For a small group of patients, that reading keeps coming back month after month, year after year, with no obvious reason. Clinicians call it nonsuppressible viremia, and it has long been a genuinely awkward problem.

It affects fewer than one in a hundred people on long-term therapy, but the consequences ripple outward: extra clinic visits, changes to medication, the quiet suspicion from some providers that the patient simply isn’t taking their pills. Now a team at Johns Hopkins, working with collaborators across the United States, Canada and Denmark, has pinned down what is actually going on in most of these cases. And the answer is reassuring in a way few expected.

The virus showing up in the blood is, for the most part, broken.

Writing in Nature Communications, the researchers looked at plasma from more than 50 people whose virus kept surfacing despite faultless treatment. In about 95 per cent of cases, the HIV genetic material floating in their blood carried a crippling flaw, a mutation or deletion in a stretch of RNA called the 5′ leader. This region acts as a kind of control panel for the virus, governing how it copies and packages itself. Damage it, and the virus can still be made, but it can’t infect anything.

A factory still running, making faulty goods

Here’s the wrinkle that makes this counterintuitive. Modern HIV drugs, which have been around since 1996, stop the virus from infecting fresh immune cells. What they can’t do is reach back into cells that were infected long ago and silence them. Most of those cells stay quiet. A few, expanded into clones over the years, keep churning out viral particles, and it turns out the genomes they’re churning out are duds.

“We know that these defective proviruses cannot infect new cells, but they are still clinically relevant,” says Francesco Simonetti, the senior author and an infectious diseases physician at Johns Hopkins. “Think of how many extra visits, extra drugs, extra costs and tests they’ve been causing.”

What surprised the team was just how lopsided the picture is. Inside the reservoir of infected CD4 cells, these 5′ leader defects are rare, barely over one per cent. Yet in the blood, the defective versions accounted for nearly all of the circulating virus, around 98 per cent in the cells they examined closely. The broken genomes were massively over-represented in the plasma, and the intact, dangerous ones were the ones being quietly cleared away. Simonetti’s reading of this is that over time on treatment, the proviruses that make functional virus get pruned by the immune system, while the defective ones slip past it and accumulate.

The damage, when they mapped it, clustered with surprising precision around a single spot, the major splice donor. It’s the site where the cell’s splicing machinery, guided by something called U1 snRNA, normally latches on. Knock out the right nucleotide there and the splicing falls apart, the virus loses its ability to replicate, but transcription carries on regardless. The cell keeps reading a broken blueprint and shipping out the useless product.

A test borrowed from cancer

Spotting all this the slow way, by sequencing virus one genome at a time, is expensive and fiddly. So the team built a shortcut. Their assay, named CLAWS, for Capturing 5′ Leader Anomalies Without Sequencing, runs on digital PCR and uses two molecular probes: one that always binds, and a second that only sticks if the splice site is intact. If the second probe goes dark, the virus is broken. The trick is borrowed straight from oncology, where similar “drop-off” tests hunt for cancer mutations in cell-free DNA.

It is cheap, fast, and sensitive enough to catch nine copies of virus in a millilitre of plasma. Used on samples taken soon after people started treatment, CLAWS picked up defective genomes emerging within about a month, then watched them take over. In people who’d been on therapy for two decades, the defective forms made up more than 95 per cent of what was left.

There is a catch, naturally. The assay was built almost entirely on subtype B virus, the dominant strain in wealthy countries, and it will need checking against the diverse subtypes that drive the epidemic globally before anyone rolls it out widely. It also can’t yet read residual virus down at the single-copy level, though the researchers reckon that’s within reach.

Still, the practical payoff could land soon. A clinician who can confirm that a stubborn viral load is just defective debris could skip the extra drugs and the anxious conversations. People could qualify for hip or knee replacements, organ transplants, or cure-focused clinical trials they might otherwise have been shut out of. “From a clinical perspective, this is important because people with HIV are taught that the absolute goal of their medication is to achieve undetectable viral load and they worry,” Simonetti says.

And the broken virus may yet have something to teach. The fact that defective genomes survive while functional ones are culled hints at a vulnerability, some difference in how the immune system sees the two. Pin that down, and it might point the way toward clearing the reservoir that has kept HIV out of reach of a cure for forty years.

Read the full study in Nature Communications

Frequently Asked Questions

If the virus showing up is broken, why does it still set off the test?

Standard viral load tests detect HIV genetic material, not whether that material can actually infect anyone. A defective provirus can still be transcribed and packaged into particles that show up as detectable RNA, even though the virus inside is incapable of replicating. That’s exactly why a detectable result has historically caused so much alarm: the test couldn’t tell functional virus from broken debris. A newer assay aims to close that gap.

Does a detectable viral load always mean someone’s treatment is failing?

Not necessarily. In the large majority of cases studied here, persistent low-level virus in adherent patients came from defective genomes, not from the virus actively replicating or developing drug resistance. That distinction matters enormously, because it separates a harmless biological artefact from a true treatment failure. Confirming which is which is now becoming possible in the clinic.

Could this change whether people with HIV can get surgery or join cure trials?

Potentially, yes. A confirmed detectable reading has sometimes excluded people from procedures like joint replacements or organ transplants, and from clinical trials with strict viral-load criteria. If a clinician can show the detectable virus is defective and noninfectious, those barriers may fall away. The cost-effective new test was designed partly with that use in mind.

What’s stopping this test from being used everywhere tomorrow?

Mainly genetic diversity. The assay was validated almost entirely on the HIV subtype common in North America and Europe, and it needs further testing against the wider range of strains circulating across Africa and Asia before global use. The researchers also want to push its sensitivity down toward single-copy detection. Both look achievable, but neither is done yet.